Exotic Avian Respiratory Disease Management and Diagnostic Imaging

Exotic avian resp disease mgmt req integrative ap-praoch due to unique avian resp anatomy: unidirectional airflow, rigid lungs, 9 air sacs (cervical, clavicular, anterior/posterior thoracic, abdominal), no diaphragm, cross-current gas exchange. Pathogens: Chlamydia psittaci (psittacosis), Aspergillus spp. (aspergillosis), Mycoplasma spp., Avian metapneumovirus (aMPV), Pacheco’s virus (PsV), bacteria (E. coli, Klebsiella, Pseudomonas), parasites (tracheal mites, air sac mites). Clinical signs: dyspnea, tachypnea, open-mouth breathing, tail bobbing, nasal/ocular discharge, sneezing, voice change, exercise intolerance. Dx challenge: subtle early signs, stress-sensitive pts, minimal cough reflex. Dx workflow: detailed hx (origin, diet, env, exposure, molting status), physical ex (endoscopy-assisted oropharyngeal exam), CBC (heterophilia, leukocytosis), biochem (elevated LDH, AST in hepatic resp involv), serology (MAT, ELISA for C. psittaci), PCR (multi-swab: choanal, fecal, respiratory exudate), culture (fungi, bacteria), Ag tests. Imaging: radiography (DV/LAT whole-body; use high mA, short exp to reduce motion), radiographic signs: air sac opacity, lung consolidation, perivisceral haziness, bone lysis (fungal inv), cardiac silhouette obscuration. Limitations: superimposition, low soft-tissue contrast. Adv imaging: CT (gold std for resp eval), high-res CT (HRCT) reveals nodules, granulomas, airway wall thickening, early bone erosion. CT protocols: 0.6–1.25 mm slice, 120 kVp, 100–200 mA, breath-hold (anesthetized pt), IV iodinated contrast for vascular/perfusion eval. PET-CT emerging in neoplastic resp ddx. Endoscopy: rigid endoscope (1.9–2.7 mm), direct vis of syrinx, primary bronchi, air sacs; allows biopsy, lavage (BAL), fungal hyphae vis. BAL: cytology (inflammatory cells, organisms), culture. US: limited due to air; useful for coelomic fluid, pericardial effusion, thyroid/parathyroid masses. Mx: iso, supp care (O2, heat, fluid thx), ABX (doxycycline 1st-line for C. psittaci; enrofloxacin for GNR), antifungals (voriconazole > itraconazole for aspergillosis; monitor LFTs), NSAIDs (meloxicam), nebulization (amphotericin B, enrofloxacin, N-acetylcysteine). Surgery: laser resection of granulomas, air sac cannulation for chronic empyma. Vaccine: aMPV vac in psittacines (EU), poxvirus vector platforms in dev. Prognosis: guarded for aspergillosis (chronicity, late dx), fair for early bacterial infx. Critical pitfalls: over-sedation (hypoxemia), misinterpreting normal air sac lines as pathology, dx delay due to non-specific signs, inappropriate ABX (e.g., amoxicillin ineffective due to beta-lactamase). Prevent: biosecurity, quarantines, air filtration (HEPA), humidity control (40–60%), minimize dust (paper bedding > litter). Species var: psittacines (high C. psittaci risk), raptors (aspergillosis post-trauma), passerines (mycoplasma), waterfowl (bacterial rhinitis). Future: AI-assisted CT segm for lesion vol quant, CRISPR-based pathogen det, nano-inhalers for targeted drug deliv. Mx must integrate imaging, lab, clin pres for optimal outc.